| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
|
|
|
||||||
|
||||||||
Journal Article |
Monoclonal Antibodies Unit, Biotechnology Program, Spanish National Cancer Centre (CNIO), Madrid, Spain. jgarcia@cnio.es
BACKGROUND AND OBJECTIVES: The positive regulatory domain I (PRDM1) protein or BLIMP-1, belonging to the PRDM gene family of transcriptional repressors, is a key regulator of terminal differentiation in B-lymphocytes and is critical for plasma cell differentiation. DESIGN AND METHODS: Here we document the expression of PRDM1 in normal and neoplastic lymphoid cells, through the use of a monoclonal antibody that recognizes the molecule in paraffin-embedded tissue sections. A large series of B and T-cell lymphomas (679 cases) was studied, using tissue microarrays. RESULTS: Multiple myeloma, plasmacytoma and lymphoplasmacytic lymphoma cases (n=19) were positive. Plasmablastic lymphoma, oral mucosa-type (n=15), were also found to be positive. PRDM1 protein was expressed in some cases of B-cell neoplasia, i.e. chronic lymphocytic leukemia/small lymphocytic lymphoma (15%), diffuse large B-cell lymphoma (43%), classical Hodgkin's lymphoma (41%) and also in T-cell lymphoma (23%). INTERPRETATION AND CONCLUSIONS: Most B-neoplastic cells showing plasmablastic differentiation were PRDM1-positive. Unexpectedly, a subset of diffuse large B-cell lymphoma expressed PRDM1, lacked detectable plasmablastic or immunoblastic changes and displayed more aggressive behavior, with a shorter failure-free survival. In contrast to normal B-cells, diffuse large B-cell lymphoma cases with increased PRDM1 expression co-expressed BCL-6 and MUM1/IRF4, confirming that PRDM1 expression in these tumors is insufficient to drive the full genetic program associated with plasmacytic differentiation.
This article has been cited by other articles:
|
|
 |
|
  K. Nie, M. Gomez, P. Landgraf, J.-F. Garcia, Y. Liu, L. H.C. Tan, A. Chadburn, T. Tuschl, D. M. Knowles, and W. Tam MicroRNA-Mediated Down-Regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg Cells: A Potential Pathogenetic Lesion in Hodgkin Lymphomas Am. J. Pathol., July 1, 2008; 173(1): 242 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Marafioti, J. C. Paterson, E. Ballabio, K. K. Reichard, S. Tedoldi, K. Hollowood, M. Dictor, M.-L. Hansmann, S. A. Pileri, M. J. Dyer, et al. Novel markers of normal and neoplastic human plasmacytoid dendritic cells Blood, April 1, 2008; 111(7): 3778 - 3792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-L. Zhao, Y.-Y. Liu, Q.-L. Zhang, L. Wang, C. Leboeuf, Y.-W. Zhang, J. Ma, J.-F. Garcia, Y.-P. Song, J.-M. Li, et al. PRDM1 is involved in chemoresistance of T-cell lymphoma and down-regulated by the proteasome inhibitor Blood, April 1, 2008; 111(7): 3867 - 3871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Tam, M. Gomez, and K. Nie Significance of PRDM1{beta} expression as a prognostic marker in diffuse large B-cell lymphomas Blood, February 15, 2008; 111(4): 2488 - 2489. [Full Text] [PDF]
|
|
|
|
|
|
W.-L. Zhao, A. Janin, and S.-J. Chen Response: Multiple role of PRDM1{beta} involvement in diffuse large B-cell lymphoma Blood, February 15, 2008; 111(4): 2489 - 2490. [Full Text] [PDF]
|
|
|
|
|
|
S. Montes-Moreno, G. Roncador, L. Maestre, N. Martinez, L. Sanchez-Verde, F. I. Camacho, J. Cannata, J. L. Martinez-Torrecuadrada, Y. Shen, W. C. Chan, et al. Gcet1 (centerin), a highly restricted marker for a subset of germinal center-derived lymphomas Blood, January 1, 2008; 111(1): 351 - 358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-Y. Liu, C. Leboeuf, J.-Y. Shi, J.-M. Li, L. Wang, Y. Shen, J.-F. Garcia, Z.-X. Shen, Z. Chen, A. Janin, et al. Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma Blood, July 1, 2007; 110(1): 339 - 344. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
